Development of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosis
- 20 March 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 145 (12) , 1321-1332
Abstract
Sclerosis is a highly morbid manifestation of chronic graft-versus-host disease (cGVHD), associated with distressing symptoms and significant long-term disability. A patient-reported outcome (PRO) measure for cGVHD-associated sclerosis is essential to advance therapeutic trials. We aimed to develop a PRO for adults with cGVHD-associated sclerosis and evaluate and refine its content validity. Adults aged ≥18 years with cGVHD-associated sclerosis participated in semistructured interviews to identify salient symptoms and functions. Sclerosis-relevant symptoms and functions from existing PROs were also used to prompt discussion of topics not spontaneously mentioned. Symptoms and functions (subcodes) of importance were clustered and mapped to overarching domains (codes) using inductive analysis, and candidate items were developed. Cognitive interviews were used to evaluate content validity of the items, response options, recall period, and respondent instructions. Thirty-six open-ended interviews, conducted to saturation, revealed the breadth of the patient experience with cGVHD-associated sclerosis including 5 overarching domains: (1) skin changes, (2) symptoms, (3) emotional and social functioning, (4) mobility restrictions, and (5) activity limitations. A pool of 54 items was tested and iteratively refined through cognitive debriefing interviews (n = 25). Phrasing changes were made to improve relevance and comprehension. One item was removed, and 2 items were added to address respondent feedback, resulting in 55 items. Results support the relevance, comprehensibility, and comprehensiveness of the provisional Lee Symptom Scale–Skin Sclerosis. Concept elicitation and cognitive interviewing have informed the development of the Lee Symptom Scale–Skin Sclerosis. Psychometric testing and determination of minimal clinically important differences are underway in an external cohort to validate the PROs.Keywords
This publication has 44 references indexed in Scilit:
- Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host DiseaseJAMA Dermatology, 2019
- COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi studyQuality of Life Research, 2018
- Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2016
- Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group ReportTransplantation and Cellular Therapy, 2015
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2014
- Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group ReportTransplantation and Cellular Therapy, 2006
- The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: An evaluation of their measurement propertiesArthritis Care & Research, 2005
- Recovery and Long-term Function After Hematopoietic Cell Transplantation for Leukemia or LymphomaJAMA, 2004
- Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients With Skin DiseasesArchives of Dermatology, 1997